易明医药(002826.SZ)：预计2025年净利润同比增长61.12%～122.08%

Core Viewpoint - Yiming Pharmaceutical (002826.SZ) expects a net profit attributable to shareholders of 74 million to 102 million yuan for 2025, representing a year-on-year growth of 61.12% to 122.08% [1] - The net profit after deducting non-recurring gains and losses is projected to be between 39 million and 54 million yuan, indicating a year-on-year increase of 111.42% to 192.74% [1] Group 1 - The company is focusing on developing its own products in line with industry trends and policy directions [1] - Significant resources are being allocated to enhance the value and market share of self-produced products [1] - The sales growth of the core proprietary product, Miglitol tablets, has contributed to the overall profit increase, laying a foundation for the company's long-term stable development [1]